MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.
She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.
MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.
The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.
On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."
The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.
This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.
A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.
These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.
Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:
The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.
It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.
In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.
This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.
Credit: Canva
UK health officials have identified seven more cases of meningitis, as part of the latest outbreak in Kent, taking the total number of cases to 27. They expect the numbers to rise in the coming days.
The UK Health Security Agency noted that it has expanded the Meningitis B vaccine regimen to everyone who has been offered preventative antibiotic treatment as part of this outbreak.
“15 laboratory cases are confirmed and 12 notifications remain under investigation, bringing the total to 27,” the UKHSA said in a statement.
“Currently, cases have been confirmed in students at 4 schools in Kent, as well as one student at a higher education institution in London (who is confirmed to be directly linked to the outbreak),” it added.
Two students -- a 21-year-old student at the University of Kent and a teenage student at a school in the town of Faversham have died in the outbreak.
A 9-month-old baby from Folkestone is reportedly battling for life in the intensive care unit.
Meanwhile, another university in the city confirmed a case of meningitis. The student at Canterbury Christ Church is believed to be a man who was at the nightclub and part of the initial cluster of 20 known cases, who visited Club Chemistry in Canterbury between March 5 and 7.
"We are not in the position yet to say definitively that it's been contained," Dr Anjan Ghosh, Director of Public Health at Kent County Council, told BBC Radio, adding that secondary transmissions needed to be ruled out.
Calling the outbreak “unprecedented”, Health Minister Wes Streeting said: “The number of suspected cases was expected to increase in the coming days because the disease had a seven- to 10-day incubation period”, Reuters reported.
In a typical year, Britain sees about 350 cases, roughly one per day, according to government estimates.
In addition to the approximately 5,000 students who were initially contacted, vaccination will now be extended to everyone who has been offered preventative antibiotic treatment as part of this outbreak, the UKHSA said.
While it remains unclear why the outbreak has been so large, “the large number of cases all originating from what seems to be a single event” is particularly striking, Prof Robin May, the chief scientific officer at the UKHSA, told the BBC Breakfast.
May said that "there might be something about the kind of behaviors that individual people are doing." Another probable reason "is that the bacteria may have evolved to be better at transmitting".
Both the UKHSA and the European Centre for Disease Prevention and Control maintain that the risk of invasive meningococcal disease to the general population in Europe is "very low".
Also read: From Vaping to Worm Attack: 5 Unimaginable Ways to Contract Meningitis
The UKHSA noted that the key intervention to protect people and halt the spread remains for people to come forward for antibiotic treatment -- effective in preventing contraction and spreading in 90 percent of cases.
In addition, a targeted MenB vaccination program is also being introduced for longer-term protection.
“By extending the vaccination program to everyone who has been offered preventative antibiotics, we are taking an important additional step to protect those most likely to have been exposed. The message is simple: if you have had the antibiotic, you are also eligible for the vaccination,” said Professor Susan Hopkins, Chief Executive of the UKHSA.
However, Trish Mannes, UKHSA Regional Deputy Director for the South East, noted that even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.
The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.
Common symptoms include:
Credit: iStock
The widespread use of Azithromycin to treat hospitalized patients during the COVID-19 pandemic increased the risk of antimicrobial resistance -- a major global health problem, according to a new study, published in the journal Nature Microbiology.
Scientists at the University of California-San Francisco (UCSF) noted that using azithromycin inappropriately for even a single day can trigger antibiotic resistance in the respiratory tract.
While azithromycin is effective against bacterial infections that cause strep throat, pneumonia, and sexually transmitted diseases, it does not work against viruses.
"We've known for years that antibiotics don't treat viral infections, but these results were striking," said Chaz Langelier, from UCSF.
"That we could see resistance genes turning on in the respiratory tract within a day tells us the consequences of unnecessary antibiotic use aren't theoretical or long-term. They're immediate, measurable, and biologically real," Langelier added.
The study analyzed nasal swabs of 1,164 adults hospitalized for COVID-19 to examine the changes that occurred in the microbiome of hospitalized patients who were treated for COVID.
Compared to people who received no antibiotics, patients administered azithromycin reported changes that persisted for more than a week. These include:
Antimicrobial resistance (AMR) occurs when germs develop the ability to defeat the drugs designed to kill them.
It is one of the 10 top global health threats, undermining the effectiveness of essential treatments and placing millions at risk of untreatable infections.
As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.
In the US alone, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to the CDC's 2019 Antibiotic Resistance (AR) Threats Report.
The WHO, in a 2025 report, noted that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments.
Between 2018 and 2023, antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual increase of 5-15 percent.
About 16 per cent of COVID-19 deaths went uncounted early in the pandemic in the US, according to a separate study, published by the journal Science Advances.
While about 840,000 COVID deaths were reported on death certificates in 2020 and 2021, the researchers using artificial intelligence (AI) decoded that as many as 155,000 unrecognised additional deaths likely occurred in that time outside of hospitals.
Credit: J&J/Canva
The US Food and Drug Administration has approved Johnson & Johnson's once-daily pill for psoriasis -- a chronic skin disease.
Icotyde is an interleukin-23 (IL-23) receptor antagonist approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older.
Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily pill has been found safe and also delivers complete skin clearance.
Also Read: Why Regulatory Clarity Is Important for Safe Aesthetic Procedures in India
In the statement, J&J said that the approval will lead to a first-line systemic treatment of plaque psoriasis with a targeted oral peptide.
“Icotyde delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once‑daily pill, making it an easy addition to a patient’s routine,” said Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health.
The novel pill also aligns with the recent International Psoriasis Council guidance that suggests transitioning to systemic therapy if two cycles of topical medications applied for four weeks fail to bring meaningful improvement.
Icotyde will prove to be “a potential game‑changer for many adult and adolescent patients”, Gold said.
The FDA’s approval is based on an unprecedented body of evidence from the phase three clinical trial, which simultaneously evaluated Icotyde in adults and adolescents, and found it a safe and effective oral pill, and also better than injectables and topical creams.
According to analysts from Wall Street, Icotyde has "blockbuster potential," and the once-daily medication could capture significant market share from injectables like Skyrizi and J&J's own Tremfya, Reuters reported.
J&J is also studying the drug, chemically known as icotrokinra, for ulcerative colitis, psoriatic arthritis, and Crohn's disease.
Psoriasis develops when the body makes skin cells too quickly. It causes skin cells to pile up and form visible patches or spots on the skin, which may be itchy or painful.
The condition, however, is not contagious.
According to the National Psoriasis Foundation, the skin disease affects 8 million Americans and more than 125 million people worldwide.
The condition impacts physical comfort and quality of life, especially when lesions are on visible or sensitive areas.
The plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales. They can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.
Icotyde is currently approved in the US for the treatment of people with moderate-to-severe plaque. It can be used by
© 2024 Bennett, Coleman & Company Limited